Obicetrapib, an experimental CETP inhibitor already known for lowering LDL cholesterol and raising HDL cholesterol in cardiovascular disease, slowed progression of a key Alzheimer’s biomarker (p-tau217) over 12 months. The effect was most notable in APOE4 carriers, who are at highest risk for both cardiovascular disease and Alzheimer’s.
Study Details
The …
